Inducing programmed necrosis, the quinone-based compounds activate the molecular pathway that causes the premature death of cancerous cells and tissue.
The compounds are also able to target various solid tumors that are difficult to treat including pancreatic and lung cancers, according to the research.
In addition, research suggests that the new class of quinone-based compounds express greater potency than other molecules in the same class such as ß-lapachone.
StemPar Sciences CEO Barry Sherman said the company views the exclusive worldwide license as an important part of its growing cancer metabolism IP estate.
"Indeed, this intellectual property has the potential to become a vital ingredient in the quest to develop novel cancer medicines based on the science of cancer metabolism."